Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

NCT04221412 · clinicaltrials.gov ↗

NO_LONGER_AVAILABLE

Status

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus

Interventions

DRUG: JNJ-53718678

Sponsor

Janssen Sciences Ireland UC